Biotech stocks dip as Trump administration mulls patent fee overhaul

Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE: XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.

According to The Wall Street Journal, Commerce Department officials are discussing a plan to charge patent holders between 1% and 5% of their overall patent value. This potential change, being considered by Commerce Secretary Howard Lutnick as part of efforts to raise revenue and reduce the government’s budget deficit, could generate tens of billions of dollars.

The proposed fee structure would represent a fundamental shift in the 235-year-old patent system, which currently requires patent holders to pay relatively modest flat fees totaling up to approximately $10,000 over multiple years. Under the new system, these costs would increase dramatically for many patent holders, functioning essentially as a property tax on intellectual property.

This potential change could have significant implications for biotech companies, which rely heavily on patent protection for their drug developments and innovations. The pharmaceutical and biotechnology sectors typically maintain extensive patent portfolios to protect their research investments and ensure market exclusivity for their products.

The news particularly affected major players in the biotech space, with companies like Pfizer (NYSE: PFE) trading lower during Monday’s session as investors assessed the potential impact of higher patent-related costs on future profitability.

You May Also Be Interested In

• Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
• Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities
• California-led coalition sues to block $110 billion Warner Bros.-Paramount merger